Background and Aim: The prevalence and clinical significance of extrahepatic autoimmune diseases (EHAIDs) have not been evaluated in a large cohort of primary biliary cholangitis (PBC). Methods: The medical records of 1554 patients with PBC from 20 international centers were retrospectively reviewed. Development of decompensated cirrhosis (ascites, variceal bleeding, and/or hepatic encephalopathy) and hepatocellular carcinoma were considered clinical endpoints. Results: A total of 35 different EHAIDs were diagnosed in 440 (28.3%) patients with PBC. Patients with EHAIDs were more often female (92.5% vs 86.1%, P < 0.001) and seropositive for anti-mitochondrial antibodies (88% vs 84%, P = 0.05) and antinuclear antibodies and/or smooth muscle antibodies (53.8% vs 43.6%, P = 0.005). At presentation, patients with EHAIDs had significantly lower levels of alkaline phosphatase (1.76 vs 1.98 × upper limit of normal [ULN], P = 0.006), aspartate aminotransferase (1.29 vs 1.50 × ULN, P < 0.001), and total bilirubin (0.53 vs 0.58 × ULN, P = 0.002). Patients with EHAIDs and without EHAIDs had similar rates of GLOBE high-risk status (12.3% vs 16.1%, P = 0.07) and Paris II response (71.4% vs 69.4%, P = 0.59). Overall, event-free survival was not different in patients with and without EHAIDs (90.8% vs 90.7%, P = 0.53, log rank). Coexistence of each autoimmune thyroid diseases (10.6%), Sjögren disease (8.3%), systemic sclerosis (2.9%), rheumatoid arthritis (2.7%), systemic lupus erythematosus (1.7%), celiac disease (1.7%), psoriasis (1.5%), and inflammatory bowel diseases (1.3%) did not influence the outcome. Conclusions: Our study confirms that EHAIDs are frequently diagnosed in patients with PBC. The presence of EHAIDs may influence the clinical phenotype of PBC at presentation but has no impact on PBC outcome.

Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome / Efe C.; Torgutalp M.; Henriksson I.; Alalkim F.; Lytvyak E.; Trivedi H.; Eren F.; Fischer J.; Chayanupatkul M.; Coppo C.; Purnak T.; Muratori L.; Werner M.; Muratori P.; Rorsman F.; Onnerhag K.; Nilsson E.; Heurgue-Berlot A.; Demir N.; Semela D.; Kiyici M.; Schiano T.D.; Montano-Loza A.J.; Berg T.; Ozaslan E.; Yoshida E.M.; Bonder A.; Marschall H.-U.; Beretta-Piccoli B.T.; Wahlin S.. - In: JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 0815-9319. - STAMPA. - 36:4(2021), pp. 936-942. [10.1111/jgh.15214]

Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome

Muratori L.;Muratori P.;
2021

Abstract

Background and Aim: The prevalence and clinical significance of extrahepatic autoimmune diseases (EHAIDs) have not been evaluated in a large cohort of primary biliary cholangitis (PBC). Methods: The medical records of 1554 patients with PBC from 20 international centers were retrospectively reviewed. Development of decompensated cirrhosis (ascites, variceal bleeding, and/or hepatic encephalopathy) and hepatocellular carcinoma were considered clinical endpoints. Results: A total of 35 different EHAIDs were diagnosed in 440 (28.3%) patients with PBC. Patients with EHAIDs were more often female (92.5% vs 86.1%, P < 0.001) and seropositive for anti-mitochondrial antibodies (88% vs 84%, P = 0.05) and antinuclear antibodies and/or smooth muscle antibodies (53.8% vs 43.6%, P = 0.005). At presentation, patients with EHAIDs had significantly lower levels of alkaline phosphatase (1.76 vs 1.98 × upper limit of normal [ULN], P = 0.006), aspartate aminotransferase (1.29 vs 1.50 × ULN, P < 0.001), and total bilirubin (0.53 vs 0.58 × ULN, P = 0.002). Patients with EHAIDs and without EHAIDs had similar rates of GLOBE high-risk status (12.3% vs 16.1%, P = 0.07) and Paris II response (71.4% vs 69.4%, P = 0.59). Overall, event-free survival was not different in patients with and without EHAIDs (90.8% vs 90.7%, P = 0.53, log rank). Coexistence of each autoimmune thyroid diseases (10.6%), Sjögren disease (8.3%), systemic sclerosis (2.9%), rheumatoid arthritis (2.7%), systemic lupus erythematosus (1.7%), celiac disease (1.7%), psoriasis (1.5%), and inflammatory bowel diseases (1.3%) did not influence the outcome. Conclusions: Our study confirms that EHAIDs are frequently diagnosed in patients with PBC. The presence of EHAIDs may influence the clinical phenotype of PBC at presentation but has no impact on PBC outcome.
2021
Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome / Efe C.; Torgutalp M.; Henriksson I.; Alalkim F.; Lytvyak E.; Trivedi H.; Eren F.; Fischer J.; Chayanupatkul M.; Coppo C.; Purnak T.; Muratori L.; Werner M.; Muratori P.; Rorsman F.; Onnerhag K.; Nilsson E.; Heurgue-Berlot A.; Demir N.; Semela D.; Kiyici M.; Schiano T.D.; Montano-Loza A.J.; Berg T.; Ozaslan E.; Yoshida E.M.; Bonder A.; Marschall H.-U.; Beretta-Piccoli B.T.; Wahlin S.. - In: JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 0815-9319. - STAMPA. - 36:4(2021), pp. 936-942. [10.1111/jgh.15214]
Efe C.; Torgutalp M.; Henriksson I.; Alalkim F.; Lytvyak E.; Trivedi H.; Eren F.; Fischer J.; Chayanupatkul M.; Coppo C.; Purnak T.; Muratori L.; Werner M.; Muratori P.; Rorsman F.; Onnerhag K.; Nilsson E.; Heurgue-Berlot A.; Demir N.; Semela D.; Kiyici M.; Schiano T.D.; Montano-Loza A.J.; Berg T.; Ozaslan E.; Yoshida E.M.; Bonder A.; Marschall H.-U.; Beretta-Piccoli B.T.; Wahlin S.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/798183
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 31
social impact